LUCD vs CDXS vs GKOS vs GEVO vs NVCR

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Analysts rate Lucid Diagnostics Inc. (LUCD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -91. 2% for Lucid Diagnostics Inc. (LUCD). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus GEVO's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lucid Diagnostics Inc.

(LUCD) is the lower-risk stock at 0. 72β versus Codexis, Inc. 's 2. 23β — meaning CDXS is approximately 211% more volatile than LUCD relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 4% for Lucid Diagnostics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NovoCure Limited (NVCR) is the more profitable company, earning -20.

8% net margin versus -1047. 6% for Lucid Diagnostics Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -1059. 6% for LUCD. At the gross margin level — before operating expenses — CDXS leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lucid Diagnostics Inc.

(LUCD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Codexis, Inc. (CDXS) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LUCD: -91. 2%, CDXS: -11. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LUCD (Healthcare) and CDXS (Healthcare) and GKOS (Healthcare) and GEVO (Basic Materials) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LUCD is a small-cap high-growth stock; CDXS is a small-cap high-growth stock; GKOS is a small-cap high-growth stock; GEVO is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.